Apellis Pharmaceuticals Price To Sales vs. Book Value Per Share

APLS Stock  USD 31.91  1.14  3.70%   
Based on Apellis Pharmaceuticals' profitability indicators, Apellis Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Apellis Pharmaceuticals' ability to earn profits and add value for shareholders.

Apellis Pharmaceuticals Price To Sales Ratio

33.56

At this time, Apellis Pharmaceuticals' Price To Sales Ratio is comparatively stable compared to the past year. Days Sales Outstanding is likely to gain to 199.50 in 2024, whereas Operating Cash Flow Sales Ratio is likely to drop (1.57) in 2024. At this time, Apellis Pharmaceuticals' Income Tax Expense is comparatively stable compared to the past year. Interest Income is likely to gain to about 22 M in 2024, despite the fact that Operating Income is likely to grow to (491.3 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.990.8525
Fairly Up
Slightly volatile
For Apellis Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Apellis Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Apellis Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Apellis Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Apellis Pharmaceuticals over time as well as its relative position and ranking within its peers.
  

Apellis Pharmaceuticals' Revenue Breakdown by Earning Segment

Check out Trending Equities.
For more information on how to buy Apellis Stock please use our How to Invest in Apellis Pharmaceuticals guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apellis Pharmaceuticals. If investors know Apellis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apellis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.03)
Revenue Per Share
5.811
Quarterly Revenue Growth
0.783
Return On Assets
(0.16)
Return On Equity
(1.07)
The market value of Apellis Pharmaceuticals is measured differently than its book value, which is the value of Apellis that is recorded on the company's balance sheet. Investors also form their own opinion of Apellis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Apellis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apellis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Apellis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apellis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Apellis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apellis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Apellis Pharmaceuticals Book Value Per Share vs. Price To Sales Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Apellis Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Apellis Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Apellis Pharmaceuticals is rated fifth in price to sales category among its peers. It is rated second in book value per share category among its peers creating about  0.36  of Book Value Per Share per Price To Sales. The ratio of Price To Sales to Book Value Per Share for Apellis Pharmaceuticals is roughly  2.75 . At this time, Apellis Pharmaceuticals' Price To Sales Ratio is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Apellis Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Apellis Book Value Per Share vs. Price To Sales

Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

Apellis Pharmaceuticals

P/S

 = 

MV Per Share

Revenue Per Share

 = 
5.35 X
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

Apellis Pharmaceuticals

Book Value per Share

 = 

Common Equity

Average Shares

 = 
1.94 X
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.

Apellis Book Value Per Share Comparison

Apellis Pharmaceuticals is currently under evaluation in book value per share category among its peers.

Apellis Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Apellis Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Apellis Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Apellis Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Apellis Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-3.5 M-3.4 M
Operating Income-517.1 M-491.3 M
Income Before Tax-526.5 M-500.2 M
Total Other Income Expense Net-9.4 M-9.8 M
Net Loss-528.6 M-502.2 M
Net Loss-528.6 M-502.2 M
Net Loss-587 M-557.6 M
Income Tax Expense2.1 M2.2 M
Net Interest Income-8.6 M-9.1 M
Interest Income20.9 M22 M
Change To Netincome174.9 M183.7 M
Net Loss(4.45)(4.68)
Income Quality 1.13  0.65 
Net Income Per E B T 1.00  0.80 

Apellis Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Apellis Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Apellis Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Apellis Pharmaceuticals' important profitability drivers and their relationship over time.

Use Apellis Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Apellis Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Apellis Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Apellis Pharmaceuticals Pair Trading

Apellis Pharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to Apellis Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Apellis Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Apellis Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Apellis Pharmaceuticals to buy it.
The correlation of Apellis Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Apellis Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Apellis Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Apellis Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Apellis Pharmaceuticals position

In addition to having Apellis Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Rubber and Plastic Products Thematic Idea Now

Rubber and Plastic Products
Rubber and Plastic Products Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Rubber and Plastic Products theme has 27 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Rubber and Plastic Products Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Apellis Stock Analysis

When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.